USC Scientists Find 1 Lead Compound to Curb Alzheimer's Inflammation in APOE4 Carriers
Updated
Updated · ScienceDaily · May 26
USC Scientists Find 1 Lead Compound to Curb Alzheimer's Inflammation in APOE4 Carriers
5 articles · Updated · ScienceDaily · May 26
USC researchers identified a lead cPLA2 inhibitor that cut harmful enzyme activation in human brain cells under Alzheimer's-related stress and crossed the blood-brain barrier in mice.
The work targets cPLA2, an enzyme tied to brain inflammation in APOE4 carriers; researchers found higher cPLA2 activity tracked with greater Alzheimer's risk among people with the high-risk gene.
Billions of molecules were screened computationally to find compounds selective enough to damp cPLA2 without broadly blocking related PLA2 enzymes needed for normal brain function.
Mouse studies showed the compound affected neuroinflammatory pathways linked to Alzheimer's, but the team said the next phase is to test whether modulating the pathway is safe and meaningful in humans.
The findings, published in npj Drug Discovery, point to inflammation-focused treatment strategies for Alzheimer's and potentially other neurodegenerative disorders.
AI drastically cuts drug discovery time. How soon will this promising brain inflammation blocker be available for human trials?
AI found a new Alzheimer's drug. But could the true cause be inflammation in the gut, not just the brain?
BRI-50460: First-in-Class cPLA2 Inhibitor Targets APOE4-Driven Neuroinflammation in Alzheimer’s—Preclinical Results and Future Directions
Overview
A multidisciplinary team at the University of Southern California has discovered a promising new compound for Alzheimer's disease, marking a major shift in treatment strategies. Instead of focusing on traditional targets like amyloid plaques, the research targets neuroinflammation by inhibiting the enzyme cPLA2, which is especially important for people with the APOE4 gene—the strongest known genetic risk factor for Alzheimer's. This approach aims to reduce harmful brain inflammation without disrupting healthy functions, offering hope for more effective and personalized therapies for those most at risk.